Laetitia Malphettes

Laetitia Malphettes has been building and leading UCB's CMC (Chemistry Manufacturing and Controls) capacities and capabilities for Gene Therapy from 2020 until now, delivering delivering all CMC (Chemistry Manufacturing and Controls) activities pertaining to drug substance (DS), drug product (DP) and analytical development & industrialization of UCB’s advanced therapeutic medicines product portfolio externally and internally from research and throughout the products lifecycle.

Laetitia has also been leading the integration of UCB’s gene therapy capacities and capabilities into UCB’s organizations, business processes and technologies (including digitalization and IT systems). As part of the integration, she is now taking on direct reporting leadership of drug substance process sciences for gene therapy as well as synthetic molecules and biologics.

By developing talents, leveraging collaborations, data and digitalization, Laetitia is dedicated to continuously advancing science and developing innovative technology platforms that anticipate the increased growth and complexities of UCB’s product portfolio and regulations to maintain the highest standards of quality, sustainability and compliance.